NMN vs NAD: the difference explained

NMN and NAD are not two brands. NAD, usually written NAD+ when the charge matters, is a coenzyme inside cells. NMN is a smaller molecule the body can use while it is making NAD. Selling 'NAD' and selling 'NMN' can mean different ingredients, different evidence, and different labels. This page separates the chemistry from the claims. It does not tell you which bottle to buy.

The chemistry, kept short

Nicotinamide is a form of vitamin B3. The body can build NAD from nicotinamide and from other precursors. NMN sits close to NAD in that pathway, which is why Yoshino's paper calls NMN availability a rate-limiting factor in mammalian NAD synthesis, in the rodent literature that paper is summarising. In the human trial, the investigators still had to measure whether 250 mg a day changed insulin sensitivity. They did not treat the pathway diagram as the result. Yi's trial's primary idea was similar: if you give NMN, does blood NAD rise? In that trial, it did, at 300 to 900 mg a day over 60 days.

A product labeled NAD, NAD+ or NADH is not automatically NMN, and it is not automatically the substance Yoshino and Yi gave people. Nicotinamide riboside is a third molecule, also used as a precursor. It has its own trials. The precursor page covers them at the level of regulatory status.

What a label is allowed to blur

Under US supplement law, the ingredient on the Supplement Facts panel has to be the ingredient in the bottle. A front-of-pack line that says NAD while the panel says NMN is a labeling problem, not a synonym. Structure/function claims still cannot be disease claims. 'Supports cellular energy' is the sort of sentence that needs substantiation and the FDA disclaimer. 'Treats aging' or 'reverses diabetes' is not a structure/function claim. The FTC's standard is competent and reliable scientific evidence for the claim you actually make. A NAD blood test moving in Yi's NMN trial does not substantiate a disease claim for a different ingredient.

The FDA's September 29, 2025 decision, confirmed in the December 2, 2025 letter, is about NMN and the dietary-supplement definition. It does not approve NAD injections, NAD drips, or any brand. Injections and intravenous NAD are outside this page. They are medicines given in a clinic, not capsules described here.

What the human trials show

NMN means nicotinamide mononucleotide. It is one step in the chemistry that makes NAD, a coenzyme used in everyday cell metabolism. Raising NAD in a blood test is not the same thing as living longer, and it is not a disease treatment. Only two small human trials are cited, so the evidence stops there.

Yoshino and colleagues published a 10-week randomized, double-blind trial in Science in 2021. Twenty-five postmenopausal women with prediabetes, who were overweight or obese, took 250 mg of NMN a day or placebo. Muscle insulin sensitivity during a clamp was about 25 percent higher after NMN than before it, and it did not change after placebo. Muscle insulin signaling increased after NMN. Body composition, blood pressure and lipids did not show a weight-loss story. No adverse events were reported, and standard blood tests stayed unremarkable. This is an early finding in 25 people with prediabetes. It does not show that NMN treats diabetes, and it does not tell a healthy 30-year-old what will happen to them.

Yi and colleagues randomized 80 healthy middle-aged adults to placebo or 300 mg, 600 mg or 900 mg of NMN daily for 60 days. All 80 finished. Blood NAD rose at day 30 and day 60 in each NMN arm versus placebo, with the higher doses higher still. Six-minute walk distance increased more than placebo. HOMA-IR, a rough insulin-resistance number, was not different from placebo at day 60. The investigators reported no safety signal on the events and labs they monitored. A biological-age calculator differed from placebo. That output is a model, not a birthday. The paper's introduction refers to animal lifespan data. The human study did not follow anyone long enough to speak about lifespan.

The part that is reasonably repeatable in these papers is a rise in blood NAD over one to two months. One small trial found a muscle insulin-sensitivity change in a specific group of women at 250 mg a day. Walking distance changed in the larger, still short, Yi trial. Longevity, diabetes treatment, and multi-year safety are not established. EFSA's 2026 opinion judged one specified NMN safe at up to 300 mg a day for adults who are not pregnant or lactating. Safety is not efficacy, and that opinion is not an FDA finding.

Amounts the studies used

250 mg a day for 10 weeks in Yoshino. 300, 600 or 900 mg a day for 60 days in Yi, with the authors describing 600 mg as the point where NAD and walking gains looked strongest. EFSA looked at a proposed maximum of 300 mg a day of one high-purity synthetic β-NMN. None of those numbers is a personal dose. NMN is not an essential nutrient with a recommended dietary allowance. Do not read a trial protocol as instructions.

How to read a comparison without a winner

• NMN is a precursor studied in the Yoshino and Yi trials at 250 to 900 mg a day for 10 weeks or 60 days.
• NAD is the coenzyme those trials cared about. A rise in blood NAD was measured after NMN in Yi's trial. That is not a trial of an oral NAD product.
• Nicotinamide riboside is another precursor. In Great Britain the chloride form is an authorized novel food. That foreign authorization is context, not a US dose.

If you are pregnant, being treated for cancer, or already using a prescribed NAD infusion, the capsule conversation belongs with a clinician. Call 911 in an emergency. Nothing here is a reason to start or stop a medicine. A chart that puts NMN and NAD in two columns and declares a winner is not a result. The difference is chemical. The evidence cited here is about NMN, not about a product whose front label says NAD.

A label that says NAD, NAD+ or NADH is not automatically the molecule Yoshino and Yi gave people. Those trials used NMN. A rise in blood NAD after NMN is not a trial of an oral NAD product. Call 911 in an emergency, and ask a clinician licensed in your state before you add a precursor to other medicines. Call 911 in an emergency. Yoshino and Yi studied NMN, not an oral NAD product.